The nonprofit health system says it has made progress toward recovering from last year’s massive cyberattack. However, it still posted losses during the third quarter of its fiscal year.
Ascension still chasing financial turnaround after last year’s cyberattack Read More »
After discussions with the FDA, Moderna has withdrawn its application for a combination shot, which had demonstrated efficacy in eliciting antibodies in data announced earlier this month.
Moderna Shares Fall as Combo Flu/COVID-19 Vaccine Application Pulled Read More »
CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech competitor.
Medtronic plans to spin off diabetes business within 18 months Read More »
The insurer sued the CMS late last year, arguing that flooding in Broward County should have qualified as an extreme and uncontrollable event relieving Florida Blue from star ratings decreases. A federal judge disagreed.
Judge denies Florida Blue’s request to bump star ratings Read More »
BioSpace sits down with four NextGen companies that are thriving despite a multi-year down period. You will hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out. Watch now.
Webinar: Are We There Yet? Surviving and Thriving in the Never-ending Biotech Downturn Read More »
BioSpace’s NextGen companies are rising in one of the most confounding biotech markets ever experienced. Executives sounded off on how to keep your head above water during our webinar, Are We There Yet?
In Biotech’s ‘Moribund’ Market, What Does It Take to Survive? Read More »
After a tense exchange, Senator Patty Murray (D-WA) told Kennedy that by implementing sweeping cuts to the HHS, he is “enacting his budget,” which “Congress has not passed.”
RFK Claims Ignorance About HHS Research, Clinical Trial Cuts in Hearing Read More »
The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson fared better, with the FDA’s cancer advisors voting to recommend Darzalex in patients with a certain type of multiple myeloma.
Roche’s Genentech Fails to Win Adcomm Backing for Columvi Expansion Read More »
Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to use in cancer, immunology and other applications.
Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space Read More »
Unos científicos han descubierto que dos compuestos naturales, patulina y xestoquinol, son inhibidores de la enzima topoisomerasa 1, una pieza clave para el correcto funcionamiento del ADN. El hallazgo abre nuevas vías para entender y tratar enfermedades relacionadas con daños e …
Vía prometedora hacia una posible estrategia anticáncer Read More »
